Preclinical Oncology Exploration Platform

Launched in 2021, the Pre-Clinical Exploration Platform in Oncology (so-called PEPCO) is designed to facilitate, accelerate and amplify the transfer to the clinic of innovative anti-tumour therapies.

PEPCO coordinates different technical platforms at IRCM to ultimately establish an integrated structure dedicated to preclinical studies of anti-cancer therapies. In particular, PEPCO brings together the technical resources, services and expertise for the generation and in vivo use of preclinical models (including cell-line xenografts, patient-derived xenografts, or orthotopic cancer models), and their most comprehensive analysis by small animal imaging, targeted or whole-body irradiation, mass cytometry and histology.

PEPCO provides both academic and private partners with a unique entry point for these services and offers optimized monitoring of projects, from their design up to the conclusions of the study.